Stock Analiz

Orchestra BioMed Holdings, Inc. OBIO

Medicinal Chemicals and Botanical Products · IPO 2020 · data as of November 13, 2026

$7.25Market cap $571M
Open the interactive analysis →

Orchestra BioMed Holdings, Inc. (OBIO) is a healthcare company listed in the US with a market value of about $571M. In the twelve months to September 30, 2026 it had revenue of $31M and net income of -$58M, a net margin of -187.0%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -73%.

About Orchestra BioMed

Orchestra BioMed is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2020. Revenue went from $4M in 2022 to $33M in 2025, growth of about 111.6% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 219% over three years (dilution for shareholders). It spends 174% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S18.3
P/B73.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1169.2%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1300.4%
ROIC (5-yr avg.)-72.6%
Profitable years (of last 10)0
Years paying a dividend1

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$31M$33M$3M$3M$4M—
Net income-$58M-$53M-$61M-$49M-$34M-$378753
Free cash flow-$64M-$49M-$51M-$46M-$30M—
EPS (diluted)$-0.75$-1.11$-1.66$-1.48$-2.24$-0.26
Net margin-187.0%-157.4%-2313.3%-1779.7%-951.3%—
ROIC—-58.2%-101.2%-58.4%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $12.83, 77% above the current price; targets range from $10.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.33 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Orchestra BioMed pay a dividend?

Not currently.

Is Orchestra BioMed a good stock to buy?

We do not give buy or sell advice. Orchestra BioMed scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.